About Peak Bio, Inc.
https://peak-bio.comPeak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
CEO
Hoyoung Huh
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 2, 2022
Full time employees 6
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
No price data available
Market Cap $531873
52w High $0.01
52w Low $0.01
P/E 0
Volume 10.00K
Outstanding Shares 53.72M
About Peak Bio, Inc.
https://peak-bio.comPeak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2025 | $0 | $293.97 ▼ | $-323.95 ▲ | 0% | $-0 ▲ | $-306.42 ▲ |
| Q4-2024 | $0 | $374.94 ▼ | $-400.63 ▼ | 0% | $-0 ▼ | $-374.94 ▼ |
| Q3-2024 | $0 | $1.49M ▲ | $1.71M ▲ | 0% | $0.06 ▲ | $3.06M ▲ |
| Q2-2024 | $0 | $1.39M ▼ | $-2.08M ▲ | 0% | $-0.09 ▲ | $-1.61M ▲ |
| Q1-2024 | $0 | $2.21M | $-2.44M | 0% | $-0.11 | $-2.08M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2024 | $862.14K ▲ | $1.64M ▲ | $22.54M ▼ | $-20.91M ▲ |
| Q2-2024 | $235.77K ▲ | $1.43M ▼ | $24.03M ▲ | $-22.59M ▼ |
| Q1-2024 | $68.61K ▼ | $1.75M ▼ | $22.28M ▲ | $-20.53M ▼ |
| Q4-2023 | $381.65K ▲ | $2.6M ▲ | $20.75M ▲ | $-18.16M ▼ |
| Q3-2023 | $94.44K | $1.51M | $19.07M | $-17.57M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2024 | $3.97M ▲ | $-2.37M ▼ | $0 ▲ | $2.95M ▲ | $788.71K ▲ | $-2.37M ▼ |
| Q2-2024 | $-2.08M ▲ | $-905.4K ▲ | $-908.41 ▼ | $1.01M ▼ | $167.16K ▲ | $-905.4K ▲ |
| Q1-2024 | $-2.43M ▼ | $-1.42M ▲ | $-188.45 ▼ | $1.11M ▼ | $-313.04K ▼ | $-1.42M ▲ |
| Q4-2023 | $-525.44K ▼ | $-1.47M ▼ | $0 | $1.75M ▲ | $287.21K ▲ | $-1.47M ▼ |
| Q3-2023 | $410.59K | $-615.91K | $0 | $499.92K | $-119.93K | $-615.91K |
Revenue by Products
| Product | Q4-2023 | Q1-2024 | Q2-2024 | Q3-2024 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Hoyoung Huh
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 2, 2022
Full time employees 6
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0